Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice

British Journal of General Practice

Volumn 54, Issue 507, 2004, Pages 765-771

  Richardson, Gerald ^a   Godfrey, Lesley ^b   Gravelle, Hugh ^a   Watt, Ian ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Priory Medical Group   (United Kingdom)

Author keywords

Cost effectiveness; Guidelines; Hypertension

Indexed keywords

BENDROFLUMETHIAZIDE; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NURSE PRACTITIONER; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RISK REDUCTION; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FAMILY PRACTICE; FEMALE; HUMANS; HYPERTENSION; MALE; PRACTICE GUIDELINES; SENSITIVITY AND SPECIFICITY;

EID: 5444273199     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. NHS Centre for Reviews and Dissemination. Drug treatment of essential hypertension in older people Effectiveness Matters 1999: (4)2. http://www.york.ac.uk/inst/crd/em.htm (accessed 22 Jul 2004).
2. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16(6): 747-752.
3. Department of Health. Health Survey for England 2002. London: Stationary Office, 2002. http://www.publications.doh.gov.uk/stats/tables/adults2002tab3a.xls (accessed 6 Sep 2004).
4. Salvetti A, Versari D. Control of blood pressure in the community: an unsolved problem. Curr Pharm Des 2003; 9(29): 2385-2402.
5. Fahey T, Silagy C. General practitioners' knowledge of and attitudes to the management of hypertension in elderly patients. Br J Gen Pract 1994; 44(387): 446-449.
6. Hart JT. Rule of halves: implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care. Br J Gen Pract 1992; 42(356): 116-119.
7. Mulrow C, Lau J, Cornell J, et al. Pharmacotherapy for hypertension in the elderly. In: Cochrane Collaboration. The Cochrane Library. Issue 4. Oxford: Update Software, 2001. http://www.mediscope.ch/cochrane-abstracts/ab000028.htm (accessed 6 Sep 2004).
8. Mulrow CD, Cornell JA, Herrera CR, et. al Hypertension in the elderly. Implications and generalisability of randomised trials. JAMA 1994; 272(24): 1932-1938.
9. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121(5): 355-362.
10. Pearce KA, Furberg CD, Rushing J. Does antihypertensive threatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Arch Fam Med 1995; 4(11): 943-949.
11. Thijs L, Fagard R, Lijnen P, et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10(10): 1103-1109.
12. Lievre M, Leizorovicz A. Treatment of high blood pressure in patients aged over 60 years: lessons from randomized clinical trials. Cardiol Elderly. 1995; 3(3): 217-222.
13. Ramsay LE, Williams B; Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999 Sep 4; 319(7210): 630-635.
14. Mason J, Eccles M, Freemantle N, Drummond M. NICEly does it: economic analysis within evidence based clinical guidelines. Centre for Health Economics (CHE) Discussion paper 164, York: CHE, December 1998. http://www.york.ac.uk/inst/che/DP164.pdf (accessed 21 Jul 2004).
15. NHS Confederation News Releases. New GMS contract will reward family doctors for higher quality services. 21 February 2003. www.nhsconfed.org/press/releases/walesgms.asp?kh=%22new%2BGMS% 2Bcontract%2Breward%2Bfamily%2Bdoctors%2Bhigher%2Bquality%2Bservices% 22&smode=or (accessed 21 July 2004).
16. Department of Health. Health Survey for England. London: Department of Health, 1998.
17. Ebrahim S, Davey-Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. In: Cochrane Collaboration. Cochrane Library. Issue 2: CD001561. Oxford: Update Software, 2000.
18. Collins R, Peto R, MacMahon S,et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335(8693): 827-838.
19. Department of Health. Discount rates and the cost of capital. London: Department of Health, 1997. (EL (97)71.)
20. Gravelle H, Smith D. Discounting for health effects in cost benefit and cost-effectiveness analysis. Health Econ 2001; 10(7): 587-599.
21. Efron B, Tibishirani RJ. An introduction to the bootstrap. New York: Chapman and Hall, 1994.
22. Fenwick E, Claxton K, Sculpher M, Briggs A. Improving the efficiency and relevance of health technology assessment: The role of iterative decision analytic modelling. Centre for Health Economics Discussion paper 2001; 179.
23. Haq IU, Yeo, WW, Jackson PR, Ramsay LE. Should cholesterol be measured in all hypertensives? J Hum Hypertens 1995 Jun; 9(6 : 417-421.
24. Hartunian NS. The incidence and economic costs of major health impairments: a comparative analysis of cancer, motor vehicle injuries, coronary heart disease, and stroke. Lexington: Lexington Books, 1981.
25. Netten A, Curtis L. Unit costs of health and social care 2000. Canterbury: Personal Social Services Research Unit, University of Kent, 2000.
26. York Health Services Trust. GP Fundholders Tariff. York: York Health Services Trust, 1999.
27. British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1999.
28. Department of Health. NHS Reference Costs. London: Department of Health. 2000.